Pamela Stenborg
Nurse Practitioner · Fairfax, VANPI 1467601336
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 318 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 40.2% of the total. Reporting peaked in 2021 at $2,825 and has fallen 68.2% since, to $900 in 2025. Among nurse practitioner clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 318 payments — averaging $26.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$846
- Johnson & Johnson$621
- Gilead$460
- Takeda Pharmaceuticals U.S.A., Inc.$382
- E.r. Squibb & Sons, L.L.C.$341
- plus $2K from 19 others
What the payments were for
- Food & beverage$8,272100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 96 | $3,331 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 59 | $846 |
| Johnson & Johnson | 16 | $621 |
| Gilead | 17 | $460 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $382 |
| E.r. Squibb & Sons, L.L.C. | 3 | $341 |
| Nestle Healthcare Nutrition Inc. | 12 | $327 |
| Ferring Pharmaceuticals Inc. | 22 | $302 |
| QOL Medical, LLC | 12 | $297 |
| Bristol Myers Squibb | 32 | $268 |
| Intercept Pharmaceuticals, Inc. | 5 | $136 |
| Phathom Pharmaceuticals, Inc. | 1 | $124 |
| Regeneron Healthcare Solutions, Inc. | 1 | $123 |
| Daiichi Sankyo Inc. | 6 | $118 |
| Enterra Medical, Inc. | 1 | $118 |
| Pfizer | 4 | $116 |
| Janssen Scientific Affairs, LLC | 1 | $105 |
| Lilly USA, LLC | 1 | $66 |
| Braintree Laboratories, Inc. | 3 | $51 |
| Ironwood Pharmaceuticals, Inc | 3 | $51 |
| Sanofi | 2 | $41 |
| Ardelyx, Inc. | 1 | $18 |
| Redhill Biopharma Inc. | 1 | $17 |
| Merck | 1 | $17 |
| W. L. Gore & Associates, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,292 in reported general payments places this provider in the 95th percentile of 2,166 nurse practitioner providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 29 | $789,764 |
| Mesalamine | 37 | $19,642 |
| LinzessLinaclotide | 14 | $17,886 |
| Budesonide EcBudesonide | 18 | $11,261 |
| Mesalamine ErMesalamine | 27 | $4,099 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 26 | $1,727 |
| CholestyramineCholestyramine (With Sugar) | 11 | $989 |
| Pantoprazole Sodium | 99 | $946 |
| Omeprazole | 45 | $921 |
| Peg3350-Sod Sul-Nacl-Kcl-Asb-CPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 11 | $621 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 34 | $406 |
| Famotidine | 19 | $243 |
| Prednisone | 20 | $144 |
| Colesevelam Hcl | 11 | $102 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 12 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $621 | $789,76429 claims |
| AbbVieLinzess | $3,331 | $17,88614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,166 nurse practitioner providers in Virginia.
Other nurse practitioner in Fairfax
- Wendy HoltFairfax$7K
- Samantha FoxGate City$207K
- Mikel GrayCharlottesville$174K
- Kevin BrigleRichmond$166K
- Denese GomesRichmond$126K
- Ashley CarmenAlexandria$99K
- Rachel AndersonCharlottesville$90K
- Megan FrancisArlington$81K
- Elizabeth WilletteNorfolk$58K
- Lacey LyleSuffolk$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.